News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-10-04-2017
Volume12
Issue 10

Ajinomoto Althea Adds High Potency Capabilities

Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.

Ajinomoto Althea, Inc. announced on Sept. 19, 2017 that the company will open a GMP production suite in its newly constructed High Potency Products (HPP) commercial manufacturing facility in San Diego, CA. The facility is designed to develop, manufacture, test, and release HPPs including antibody drug conjugates, highly potent APIs, and other complex formulations of highly potent drugs.

The company currently offers process development and analytical services to clients from the facility and will be open for GMP bioconjugation and complex formulation in November 2017. Full manufacturing services, including high containment fill and finish, will commence in Q4 2018, as reported in a press statement on Sept. 19, 2017.

The company also announced that it secured its first manufacturing contract for the new facility.

Source: Ajinomoto Althea

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content